

6 January 2022

ASX Market Announcements Office
ASX Limited
Level 4, North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

By electronic lodgement

Dear Ms Kostopoulos,

Notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth)

Micro-X Limited (ASX:MX1) (ACN 153 273 735) (**MX1**) gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Act**) that:

- (a) on 4 January 2022, it issued 13,210 fully paid ordinary shares upon the exercise of Performance Rights issued in accordance with the Company's Employee Incentive Plan approved at its 2020 Annual General Meeting;
- (b) the shares were issued for nil consideration;
- (c) the shares referred to above were issued without disclosure under Part 6D.2 of the Act;
- (d) as at the date of this notice, MX1 has complied with:
 - (i) the provisions of Chapter 2M of the Act as they apply to MX1; and
 - (ii) section 674 of the Act; and
- (e) as at the date of this notice, there is no "excluded information" of the type referred to in sections 708A(7) and 708A(8) of the Act.

Yours sincerely



Kingsley Hall
Chief Financial Officer and Company Secretary
Micro-X Limited

– ENDS –

About Micro-X

Micro-X Limited (the **Company**) is an ASX listed hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, carbon nanotube (CNT) emitter technology. The electronic control of emitters with this technology enables x-ray products with significant reduction in size, weight and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security and defence applications. Micro-X has a fully vertically integrated design and production facility in Adelaide, Australia. A growing technical and commercial team based in Seattle is rapidly expanding Micro-X's US business.

Micro-X's product portfolio is built in four, high margin, product lines in health and security. The first commercial mobile digital radiology products are currently sold for diagnostic imaging in global healthcare, military and veterinary applications. An X-ray Camera for security imaging of Improvised Explosive Devices is in advanced development. The US Department of Homeland Security has selected Micro-X to design a next-generation Airport Checkpoint Portal with self-service x-ray. A miniature brain CT imager for pre-hospital stroke diagnosis in ambulances, is being developed with funding from the Australian Government's Medical Research Future Fund.

For more information visit: www.micro-x.com

CONTACTS

Micro-X Limited	Investor Enquiries
Peter Rowland Managing Director Tel: +61 8 7099 3966 E: admin@micro-x.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: dallen@hawkesburypartners.com jgranger@hawkesburypartners.com